(Q51379841)

English

Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.

scientific article published in March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

anti-retroviral agent

0 references

14

object named as

R S Hogg

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

author name string

J Raboud

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Anema

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

D Su

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

M B Klein

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Zakaryan

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

T Swan

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Palmer

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

S Hosein

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

M R Loutfy

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

N Machouf

10

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

J S G Montaner

11

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

S B Rourke

12

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

C Tsoukas

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

C Cooper

15

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Canadian Observational Cohort (CANOC) Collaboration

16

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

90-102

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

HIV and hepatitis C coinfection within the CAESAR study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C and Innate Immunity: Recent Advances

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Lower CD4+ T-cell number expressing CD7+ characterizes HIV/hepatitis C virus coinfection compared with HIV and hepatitis C virus monoinfection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Cognitive dysfunction in chronic hepatitis C: a review

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Antiviral antibodies in the sera of homosexual men: correlation with their lifestyle and drug usage

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Identifiers

10.1310/HCT1302-90

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51379841&oldid=1267470240"